Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jiangxi Jiangzhong Pharmaceutical Enters Distribution Business

This article was originally published in PharmAsia News

Executive Summary

Jiangxi Jiangzhong Pharmaceutical, China's leading OTC drug company, will acquire stakes in Jointown Group's subsidiary Jiangxi Jointown Pharmaceutical with 11.18 million yuan (1.62 million). At the same time, it will pump in 18.8 million yuan ($2.73 million) to increase its equity in Jiangxi Jointown, securing 51 percent of the firm in total. Analysts say the move will expand the marketshare of Jiangzhong Pharmaceutical's brand and products to gain a dominant position in Jiangxi. Jointown can bring complementary products into the region and develop its end-user market through the collaboration. Observers note the trend of pharmaceutical companies entering drug distribution to control the end-user retail market will have significant impact on the domestic industry. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel